title: Histologic changes in superficial basal cell epithelioma and Bowen's disease by intralesional injection of recombinant interleukin 2: recombinant interleukin 2 may induce redifferentiation of malignant tumor cells in vivo.
authors.forename: M
authors.initials: M
authors.lastname: Mihara
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Morimura
authors.forename: Y
authors.initials: Y
authors.lastname: Hagari
authors.forename: S
authors.initials: S
authors.lastname: Shimao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001913:Bowen's Disease / Q000473:pathology* / Q000628:therapy; D002280:Basal Cell Carcinoma / Q000473:pathology* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002454:Cell Differentiation; D004817:Epidermis / Q000473:pathology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins